• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?

    2020-06-08 05:23:46IlariaLenciMartinaMilanaGiuseppeGrassiTommasoManziaCarloGaziaGiuseppeTisoneRobertaAngelicoLeonardoBaiocchi
    World Journal of Gastroenterology 2020年18期

    Ilaria Lenci, Martina Milana, Giuseppe Grassi, Tommaso M Manzia, Carlo Gazia, Giuseppe Tisone,Roberta Angelico, Leonardo Baiocchi

    Abstract Hepatitis B virus (HBV) recurrence after liver transplantation (LT) has been described more than 50 years ago. Similarly, to other clinical conditions, in which impairment of host immune defense favors viral replication, early reports described in details recurrence and reactivation of HBV in liver transplant recipients. The evidence of a possible, severe, clinical evolution of HBV reappearance in a significant percentage of these patients, allowed to consider,for some years, HBV positivity a contraindication for LT. Moving from the old to the new millennium this picture has changed dramatically. Several studies contributed to establish efficient prophylactic protocols for HBV recurrence and with the advent of more potent anti-viral drugs an increased control of infection was achieved in transplanted patients as well as in the general immunecompetent HBV population. Success obtained in the last decade led some authors to the conclusion that HBV is now to consider just as a “mere nuisance”.However, with regard to HBV and LT, outstanding issues are still on the table: (1)A standard HBV prophylaxis protocol after transplant has not yet been clearly defined; (2) The evidence of HBV resistant strains to the most potent antiviral agents is claiming for a new generation of drugs; and (3) The possibility of prophylaxis withdrawal in some patients has been demonstrated, but reliable methods for their selection are still lacking. The evolution of LT for HBV is examined in detail in this review together with the description of the strategies adopted to prevent HBV recurrence and their pros and cons.

    Key words: Liver transplant; Hepatitis B virus; Viral recurrence; Prophylaxis;Minimization; Antiviral drug

    INTRODUCTION

    The hepatitis B virus (HBV) is a small DNA virus belonging to theHepadnaviridaefamily[1]. Despite the adoption, in several countries, of an extended vaccination campaign starting in 1992, HBV infection still represents an important health problem with 350-400 million people infected in the world[2]. Without treatment, at least one third of patients are estimated to progress to significant liver disease, including endstage liver cirrhosis and tumors. In fact, the natural history of HBV liver disease includes a spectrum of clinical conditions ranging from a non-frequent fulminant hepatitis to HBV-related hepatocellular carcinoma and/or end-stage liver disease[3,4].While vaccination and the new antiviral drugs are effective, respectively, in avoiding HBV infection and preventing the most severe sequelae of HBV disease, liver transplantation (LT) remains the main therapeutic option in patients with more severe forms of HBV liver injury[5]. However, in the early 90's the possibility to offer LT to HBV candidates was an argument of debate. In fact, it was evident that HBV disease recurrence in the graft was severe in a significant proportion of patients[6]. Moreover,an aggressive clinical form of viral reactivation, named Fibrosing Cholestatic Hepatitis, was also described in nearly 25% of HBV transplanted patients, leading to a dramatic and rapidly progressive course[7]. Therapeutic advancement and prophylactic strategies against HBV radically changed this picture in the last three decades, allowing the consideration of HBV recurrence after LT to no longer be of concern. In this review we will describe HBV viral features, its natural history, and current outcome of HBV after LT.

    NATURAL HISTORY OF HBV

    HBV, a double stranded small DNA virus, replicating by reverse transcription, is able to convert its DNA in a covalently closed circular (ccc) form when reaching the hepatocyte's nucleus. cccDNA represents a mini-chromosome containing information for antigens (HBsAg, HBeAg, and HBcAg), X protein, and polymerase production[8].The infection route is mainly represented by vertical transmission in endemic areas.The estimated risk of acquiring the infection from an HBeAg+ mother is around 80%[9]. On the other hand, sexual or needle transmission are important paths in nonvaccinated adult patients of western countries[10]. Evolution of infection is dependent on the host, the viral genetics and virus/host interaction[3,11,12]. Vertical transmission at birth is associated (without peri-natal treatment) with a lifetime infection, usually with an immune-tolerant state[11]. This clinical situation is characterized by HBeAg positivity, high levels of HBV-DNA and normal liver function tests. Conversely, in adult normal subjects, immuno-tolerance usually lasts for 2-4 wk, the time span corresponding to the HBV incubation phase. Activation of the immune system against HBV determines: (1) Decreased HBV-DNA levels; (2) Increased liver inflammation;and (3) Elevation of serum levels of liver function tests. These features characterize the immune-active phase. This stage may evolve into: (1) Infection resolution with production of high titers of HBsAb (this target is reached by more than 90% of healthy adult individuals within 6 mo of initial HBV contact); (2) Fulminant hepatitis (rarely,≤ 0.5%); or (3) HBsAg persistence and evolution to chronic hepatitis[4]. During chronic hepatitis, the seroconversion to the HBeAg negative state (with development of HBeAb titer) represents an important achievement as it corresponds to decreased levels of HBV-DNA, liver inflammation and injury[13-15]. Moreover, HBeAg seroconversion with the consequent drop in HBV-DNA serum levels has been related to reduced fibrosis progression, histological staging, and onset of cirrhosis and hepatocellular carcinoma[16-18]. A subject with an acquired HBeAg negative state is usually defined as an inactive HBV carrier, referring to a remission state of the liver disease. Unfortunately, seroreversion to an HBeAg positive condition may occur over time (in approximately 20% of patients), also transiently, leading to a “de novo”immune-active inflammatory stage. Moreover, HBeAg loss (both spontaneous and drug induced) may determine selection in the host of pre-core mutants of HBV (not producing HBeAg). These strains are not affected, during their replicative phases, by anti-HBe antibodies, thus they determine progression of liver injury in approximately 10 to 30% of patients obtaining HBeAg loss[3,5,19]. The main clinical and virological features, in the different phases of HBV chronic infection, are reported in Table 1.From the above, it is evident that host-immune-system/virus interaction is a major determinant of the presence and severity of liver injury. This result is far more evident in subjects undergoing immune system changes related to biological or immunosuppressive therapies, including the majority of transplanted patients. In this setting severe reactivation of HBV is an element of concern[20].

    HBV DURING IMMUNE SYSTEM SUPPRESSION OR MODIFICATION (DRUG-INDUCED IMPAIRMENT OF THE IMMUNE SYSTEM AS A RISK FACTOR FOR HBV REACTIVATION)

    Reactivation of HBV is represented by sudden reappearance or increase of viral DNA in the serum of a patient with a resolved or clinically silent HBV infection[20]. This condition, which may also occur spontaneously, has been reported more frequently in patients undergoing immunosuppressive therapy for malignant or non-malignant disease[21]. In an early study in non-Hodgkin lymphoma patients under chemotherapy,HBV reactivation accounted for 72% of cases in HBsAg positive subjects[22]. More importantly, viral reappearance was also observed in HBsAb/HBcAb or only HBcAb positive subjects, thus suggesting the possibility of HBV reactivation also in conditions in which the infection was considered resolved in the past. Further studies also demonstrated HBV reappearance in non-neoplastic clinical settings such as Crohn's disease[23]or rheumatologic affections[24]. Treatment with biological agents,such as B-cell depleting (i.e., rituximab) or anti-tumor necrosis factor drugs(infliximab), carries a significant risk of HBV reactivation[25]. However, standard steroid treatment may also be responsible for HBV reappearance[26]. Evolution of viral reactivation is generally thought to occur in three separate phases[20,21]. At the beginning, a rise in HBV-DNA (at least ten-fold in comparison with baseline values) is observed during immunosuppressant treatment. In the second phase, when drugs are tapered or discontinued, the inflammatory damage begins, being triggered by the host immune defense that is also, in part, restored. In the last phase, the liver damage is repaired or may progress to end-stage liver failure. The evidence of a possible dramatic evolution of HBV reactivation in liver failure prompted the adoption of strategies to counteract this preventable occurrence. First of all, an adequate screening for HBV virus, including HBcAb, is proposed in individuals undergoing chronic therapy with immunologic modifiers. Secondly, antiviral agents able to prevent or cure this clinical condition are administered according to both viral and patient's features[27-29]. However, the clinical strategies commonly employed to prevent HBV reinfection are still lacking significant scientific evidence[27]. Therefore, the question of the best approach in different clinical scenarios remains open.

    Finally, the most important clinical setting in which HBV reappearance is a relevant issue is that of transplant. Transplanted patients usually require long-term high-dose immunosuppression to prevent rejection. In HBsAg positive patients undergoing bone marrow transplantation, HBV reactivation accounts for nearly the totality of cases[30]. Even in HBsAb/HBcAb+ subjects, reappearance of active HBV is not rare,accounting for nearly 20% of cases[31]. Starting from the early eighties, HBV reactivation was reported to be very frequent in the setting of kidney and heart transplantation, and it was characterized by the insurgence of HBV chronic hepatitis[20]. Indeed, HBV reactivation or recurrence also represents an important issue in liver transplanted patients. These subjects, in fact, share the same immunosuppressive need as other transplanted patients but, at the same time, are suffering the most important sequelae of HBV before surgery. This setting probably represents the most important clinical scenario in which dramatic HBV resurgence was observed

    Phase 1: lmmune tolerant Phase 2: lmmune active Phase 3: Asymptomatic carrier Phase 4: HBV reactivationand prophylactic measures were firstly pursued. At the same time, LT was the setting in which the risk of transplant with anti-core-HBV positive liver graft was identified.

    Table 1 Main virological and biochemical features in the different clinical phases of chronic hepatitis B in HBsAg+ patients

    HBV RECURRENCE IN THE EARLY TIMES OF LIVER TRANSPLANTATION (THE PURSUIT OF AN EFFECTIVE PROPHYLACTIC STRATEGY)

    HBV recurrence/reactivation after LT was already recognized almost 50 years ago[32].In the early 90's the feasibility of LT in HBV patients remained a crucial question since several reports observed viral recurrence in nearly all transplanted subjects, with an aggressive course in the larger part of them. While graft replacement was able to transiently reduce viral load, viral resurgence in the course of immunosuppression was related to significant liver damage and cirrhosis development[6,33]. So, at that time,LT in HBsAg positive patients was considered a high risk procedure for graft and patient loss, with an unacceptable hazard in particular in HBeAg+ subjects[34]. The disappointing results, and the need to pursue a solution for HBV patients with endstage liver disease, stimulated the research for a possible prophylactic therapy after LT. In a pioneering study conducted at Paul Brousse Hospital (Villejuif, France) in the eighties, an extended passive immune-prophylaxis was tested in HBsAg positive patients after LT[35]. Despite the monthly HBsAb immunoglobulin (HBIG)administration, 29% of patients experienced HBsAg and HBV-DNA reappearance in serum, however these data demonstrated the possibility to reduce HBV recurrence after LT. In a further European retrospective study on 372 HBV liver transplanted patients (between 1977 and 1990), a reduced rate of HBV reactivation was statistically associated with the absence of HBV-DNA before transplant and again to long-term passive immune prophylaxis with HBIG[36]. The exact mechanisms of the beneficial effects of immunoglobulin in this setting are not completely clear at present. Both reduced deletion of infected hepatocytes and prevention of viral aggression of liver cells have been suggested as possible effects[37]. Starting from the mid 90's, evidence was gathered on the role of lamivudine (Lam) treatment in repressing HBV replication[38,39]. Since, at that time, only HBIG-based prophylaxis was available after LT, and this therapy was a life-long, suboptimal, expensive treatment, the evaluation of the Lam effect in this clinical setting began. In an English study, 17 HBsAg positive patients were enrolled to receive Lam 4 wk before liver transplant and to continue 1 year thereafter[40]. Twelve out of seventeen patients were transplanted. In them, Lam induced a loss of HBsAg and undetectable HBV-DNA serum levels within 4 wk of treatment and after transplant. Moreover, liver histology did not show features suggesting HBV recurrence after LT, and these results were obtained without concomitant HBIG immune prophylaxis. Unfortunately, in the same study, selection of a resistant strain to Lam was observed in one patient after 20 wk of treatment. This occurrence was characterized by reactivation of HBV and evidence of chronic hepatitis on liver tissue after 1 year. Similar to that observed in HIV therapy[41], HBV strains not-responding to Lam were characterized by mutation of polymerase at the highly conserved YMDD motif[42-44]. With regard to liver transplanted HBV patients,extended follow up of Lam resistant patients was lately reported. Resistance to Lam began to occur, typically, six months after its introduction and was sometimes characterized by severe disease recurrence[45,46]. A combination of Lam therapy with HBIG was then attempted in order to further reduce HBV recurrence after LT. In a study, fourteen HBsAg positive LT patients were treated with Lam plus HBIG[47]. In a median follow-up of one year, all patients were HBV-DNA negative in serum, thus demonstrating the superiority of combination therapy in comparison with monotherapy with either Lam or HBIG. These data were also confirmed in a study with an extended (average 31 mo) follow-up[48]. Thus, the past millennium ended with the positive perspective that prevention of HBV recurrence/reactivation in HBsAg transplanted subjects was feasible. On the basis of these results, the possible exclusion of HBV subjects from transplant lists was largely reexamined.

    HBV RECURRENCE/REACTIVATION AFTER LIVER TRANSPLANTATION IN THE THIRD MILLENNIUM (TESTING NEW THERAPEUTIC APPROACHES AND DRUGS)

    The efficacy of passive immunization, in association with Lam, was again demonstrated in retrospective studies after the year 2000[49,50]. However, since this strategy was flawed by the relevant cost of HBIG and the need of life-long administration, the possibility to induce active immunization in HBV liver transplanted patients was examined.

    HBV vaccination

    In a study on 17 HBsAg+, HBeAg and HBV-DNA negative liver transplanted patients(after at least 18 mo of HBIG treatment), the double dose administration of HBV vaccine at baseline, 1 and 6 mo was tested[51]. After vaccination 84% of patients developed an HBsAb titer. During a further follow-up of 14 mo, HBsAg reappearance was not observed. These positive results were not replicated in a following study in which three reinforced and sequential cycles of HBV vaccination determined only a 17.6% HBsAb seroconversion in HBV transplanted patients[52]. In an editorial in the same journal, the limits of this strategy in transplanted patients were discussed,underscoring the scarce vaccine efficacy during immunosuppression and the long time needed to reconstitute the immune system after its depression[53]. In conclusion, it was confirmed that HBIG and antiviral therapy were regarded as the most appropriate measures against HBV recurrence after LT[54].

    Adefovir dipivoxil

    With regard to antiviral agents, in those years, a new drug implemented the armamentarium for the therapy of HBV. Adefovir dipivoxil (ADV), a nucleotide analog inhibiting viral reverse transcriptase that was abandoned for treatment of HIV because of kidney damage when used at high dose, was licensed for HBV treatment since it was active at lower, non-toxic levels for this virus (10 mg/d). ADV treatment in the majority of immune-competent HBsAg patients (both HBeAg positive or negative) determined a clear reduction of HBV-DNA, improvement of liver histology,and normalization of liver enzymes after a 48 wk course[55,56]. Moreover, emergence of ADV resistant mutants was not observed during these trials. Despite the fact that possible long-term viral resistance to ADV remained to be assessed, the efficacy of this new antiviral drug allowed hope for a new era in which HBV could be regarded as just a “mere nuisance”[57]. Soon, ADV was employed for the treatment of Lam resistant HBV after transplant[58]. Again, a significant improvement of liver function was recorded in nearly 90% of patients, and no resistant HBV strains were selected after 48 wk of therapy. However, ADV viral resistance was then observed with prolonged follow-up[59,60]. This was characterized by a novelN236Tmutation of HBV polymerase.In spite of this, the clinical evolution in patients was not worrisome since these ADV resistant strains were easily suppressed by Lam concomitant therapy. On the base of these findings, a possible Lam + ADV concomitant treatment for HBV was suggested[61]. Data from a systematic review including 2162 HBV LT patients[62]identified the following as possible risk factors for HBV recurrence: (1) Being HBVDNA positive at transplant (8.5%vs4%); (2) Administration of low dose HBIG in the first week after LT (6.1%vs3.5%); and (3) Combination therapy with HBIG + LamvsHBIG + ADV (6.1%vs2%). This picture was destined to undergo further changes with the advent of new nucleos(t)ide analogues with high genetic barriers.

    New high genetic barrier nucleos(t)ide analogues.

    Starting from 2012, entecavir (ETV) and tenofovir dipivoxyl (TDF) were proposed by several guidelines as a first line of treatment for chronic HBV hepatitis[5,63]. In fact, both drugs were demonstrated to be very effective in clinical studies, to have an excellent safety profile, and to be affected by a minimal or absent emergence of resistant HBV strains[64-68]. In a systematic review[69]on nucleos(t)ide analogues for HBV prophylaxis after LT, the comparison between Lam + HBIGvsthe association of ETV or TDF with HBIG demonstrated the superiority of the latter treatments (HBV recurrence rate 6.1%vs1%,P< 0.001). Moreover, in the same analysis, preliminary data evidenced slightly better results with either ETV or TDF monotherapy (after HBIG discontinuation) in comparison with the canonical Lam + HBIG prophylaxis (HBV recurrence rate 3.9%vs6.1%, difference not statistically significant). These findings introduced the concept of a possible minimization of HBV prophylaxis after LT, stimulating research with this target.

    TOWARD HBV PROPHYLAXIS MINIMIZATION AFTER LT

    Several strategies have been designed to minimize HBV prophylaxis after LT. The most relevant are described in the following subparagraphs with the corresponding results. Main studies on this issue are also summarized in Table 2.

    HBIG dose reduction

    Since long-term administration of HBIG was a critical point for its high cost, that would easily reach $100.000/pts/year[70], several attempts were carried out to reduce HBIG administration and acceptable results obtained. In a 2004 study conducted in our Unit (Liver Transplant Center, University of Rome Tor Vergata), we evaluated the possibility to prevent HBV recurrence after LT by administering HBIG on demand(when HBsAb serum levels were ≤ 70 IU/L) instead of the standard monthly administration[71]. Moreover, in the same study, two different HBIG doses (5000 IU or 2000 IU) were employed. In eleven HBV patients, at low risk for reactivation (HBsAg,HBV-DNA negative) and under concomitant Lam therapy, this strategy did not determine any HBV reactivation for 1 year follow up. On the other hand, the treatment based on administration of 2000 IU HBIG on demand reduced the cost of passive immune-prophylaxis by more than 50%. In 2007, the Australasian Liver Transplant Study Group assessed the association of very-low HBIG doses (400-800 IU)+ Lam on HBV recurrence after LT[72]. This strategy accounted for a modest HBV recurrence risk of 4% in 5 years, and the results were considered highly satisfactory since the majority of patients (85%) were HBV-DNA positive at transplant.

    High-genetic barrier nucleos(t)ide analogues monotherapy

    The advent of high-genetic barrier nucleos(t)ide analogues ETV and TDF, allowed speculation on a possible prophylaxis without HBIG. ETV monotherapy, tested on 80 patients undergoing LT for HBV, was able to suppress HBV-DNA (under the lower detection limit) in nearly 99% of cases after 24 mo[73]. Extended follow up of this study(8 years) demonstrated a 92% loss of HBsAg, while HBV-DNA was undetectable in all[74]. On the other hand, discontinuation of HBIG in transplanted patients treated with TDF + HBIG did not change any viral or patient profile in a 72 wk follow-up[75].Good results with either ETV and TDF were also replicated in other studies[76,77]. In a 5-year follow up in patients discontinuing HBIG and commencing either ETV or TDF after LT, HBsAg+ seroconversion occurred in 8% of cases, while HBV-DNA reappearance was not observed[78]. On the basis of these results, the most authoritative guidelines in the field now contemplate ETV or TDF monotherapy as an efficient prophylactic measure in subjects at low risk of HBV recurrence after LT[78,79].

    Complete withdrawal of HBV prophylaxis

    In the past years, our group examined a more radical approach to HBV prophylaxis minimization. This was characterized by the complete withdrawal of antiviral drugs in well selected HBV transplanted patients. We started with the assumption that reappearance of HBV after transplantation was dependent on the presence of cccDNA in the graft. Contrary to a North American study, (including several HBeAg/HBVDNA+ patients at LT) in which total HBV-DNA and cccDNA were detected in liver tissue in 83% and 18% of cases, respectively[80], in a preliminary evaluation of HBsAg patients transplanted in our center, only 1 out of 44 was found to be positive for cccDNA[81]. Among those that were negative for liver ccc-DNA, 30 were selected and underwent sequential withdrawal of HBIG and Lam. The majority of patients (83%,n= 25) did not experience any HBV recurrence in a median follow up longer than 2 years. Five patients came back to an HBsAg positive status. Prompt resumption of HBV prophylaxis allowed infection control, avoiding any significant clinical impairment[82]. From this study, we concluded that complete withdrawal of HBV prophylaxis after LT was feasible in patients with negative serum HBV-DNA and tissue cccDNA at transplant. An editorial, in the same journal, wisely observed that the time had come for an individualized prophylaxis in HBV transplanted patients[83].In fact, recurrence of HBV was mainly reported in patients who were HBV-DNA positive at transplant (> 100.000 copies/mL) and/or HBeAg+[36,72,84]. On the other hand, those not falling in the above category were considered at low risk for HBV recurrence. In this perspective, the target of HBV-DNA negativity was to be pursued before transplant in order to perhaps minimize prophylaxis after grafting. Conversely,for high-risk patients (HBeAg, HBV-DNA positive), more robust antiviral protocols were to be considered.

    Table 2 Main studies examining prophylaxis minimization in hepatitis B virus liver transplanted patients, employing different approaches

    More recently, data on longer (6-year) follow up of this original cohort were published by our group[85]. Only 3 patients needed prophylaxis resumption (10%). Of the whole cohort, 93% remained HBsAg negative and 100% had undetectable HBVDNA. More interestingly, 60% of patients spontaneously developed an HBsAb titer >10 IU/L. This was probably related to the minimization or withdrawal of antirejection therapy that is routinely pursued in our center in patients transplanted for several years. Comment on this study appeared in a new editorial[86]. While these data were encouraging, it underscored that limits remained in the identification of low risk patients. cccDNA techniques, in fact, needed to be standardized to be widely and consistently applicable in clinical settings, but on the other hand, extra-hepatic HBV reservoirs were still a possible issue of concern.

    CONCLUSION

    Several important achievements were obtained in the last fifty years with regard to HBV liver transplanted patients. The original exclusion of these subjects from LT waiting lists, due to poor outcome, was counteracted by the adoption of effective measures to prevent HBV recurrence. At present, high genetic barrier anti-viral drugs are giving an important contribution in transplanted patients, as well as in the HBV immune-competent population. Recently, tenofovir alafenamide, a TDF analog with improved renal safety and increased ability to reduce alanine aminotransferase, was employed in LT patients with good results[87]. However, of concern, HBV mutants with resistance to TDF (the drug with the highest genetic barrier) were recently identified, underscoring the need of a new generation of HBV agents to be employed,at least, as a rescue therapy[88]. The future of LT for HBV is not completely predictable at this stage. It will, however, depend on the global burden of HBV and the possible discovery of HBV eradicating drugs.

    一级毛片电影观看| 在线 av 中文字幕| 一夜夜www| 一夜夜www| 国产成人a∨麻豆精品| 欧美zozozo另类| 嫩草影院新地址| 七月丁香在线播放| 99久久中文字幕三级久久日本| 床上黄色一级片| 日本免费a在线| 91精品伊人久久大香线蕉| 亚洲国产精品成人综合色| 久久久久久久午夜电影| 激情五月婷婷亚洲| 国产av不卡久久| 国产三级在线视频| 免费高清在线观看视频在线观看| 国产一级毛片七仙女欲春2| 身体一侧抽搐| 2022亚洲国产成人精品| 日日啪夜夜撸| 人人妻人人澡欧美一区二区| 日韩人妻高清精品专区| 汤姆久久久久久久影院中文字幕 | 亚洲熟女精品中文字幕| 五月伊人婷婷丁香| 久久久成人免费电影| 久久久久久久久大av| 亚洲熟妇中文字幕五十中出| 成人特级av手机在线观看| 在线观看美女被高潮喷水网站| 一级毛片我不卡| 超碰97精品在线观看| 日韩电影二区| 免费观看精品视频网站| 国产成人精品一,二区| 亚洲精品中文字幕在线视频 | 国产精品人妻久久久影院| 亚洲国产精品sss在线观看| 美女大奶头视频| 亚洲精品日韩在线中文字幕| 99视频精品全部免费 在线| 最近中文字幕2019免费版| 三级经典国产精品| 国产高清不卡午夜福利| 欧美不卡视频在线免费观看| av福利片在线观看| 三级国产精品欧美在线观看| 岛国毛片在线播放| 女人久久www免费人成看片| 黄色日韩在线| 国产免费一级a男人的天堂| 亚洲真实伦在线观看| 久久久久精品久久久久真实原创| 爱豆传媒免费全集在线观看| 欧美性猛交╳xxx乱大交人| 大片免费播放器 马上看| 国产精品美女特级片免费视频播放器| 亚洲精品中文字幕在线视频 | 久久精品国产亚洲av天美| 国产在线男女| 中文天堂在线官网| 亚洲18禁久久av| 99久国产av精品国产电影| 乱码一卡2卡4卡精品| 欧美日韩综合久久久久久| 婷婷六月久久综合丁香| 亚洲欧美清纯卡通| 亚洲人成网站高清观看| 汤姆久久久久久久影院中文字幕 | 啦啦啦韩国在线观看视频| 精品一区二区三区人妻视频| 国产亚洲午夜精品一区二区久久 | 少妇的逼水好多| 久久久亚洲精品成人影院| 国产精品三级大全| 亚洲精品成人av观看孕妇| 中文字幕av在线有码专区| 亚洲激情五月婷婷啪啪| 国产黄片视频在线免费观看| 亚洲不卡免费看| 波野结衣二区三区在线| 久久久久久久久大av| 99久久精品国产国产毛片| 99热这里只有是精品50| 国产乱人视频| 久久6这里有精品| 国产久久久一区二区三区| 亚洲av二区三区四区| 日韩制服骚丝袜av| 亚洲欧美清纯卡通| 亚洲欧美成人精品一区二区| 久久久久精品久久久久真实原创| 日本免费a在线| 中文字幕制服av| 看免费成人av毛片| 免费av毛片视频| 日韩av在线大香蕉| 国产综合懂色| 91午夜精品亚洲一区二区三区| 久久久久久国产a免费观看| 亚洲成人久久爱视频| 午夜免费男女啪啪视频观看| 亚洲精品亚洲一区二区| 国产综合精华液| 美女高潮的动态| 国产在线男女| 成人亚洲欧美一区二区av| 草草在线视频免费看| 丰满少妇做爰视频| 男人爽女人下面视频在线观看| 美女被艹到高潮喷水动态| 国产极品天堂在线| 偷拍熟女少妇极品色| 干丝袜人妻中文字幕| 久久久久国产网址| 国产一区亚洲一区在线观看| 国产老妇伦熟女老妇高清| 青春草视频在线免费观看| 久久久亚洲精品成人影院| 一级毛片久久久久久久久女| 乱码一卡2卡4卡精品| 纵有疾风起免费观看全集完整版 | 国产在视频线在精品| 国产有黄有色有爽视频| 草草在线视频免费看| 插阴视频在线观看视频| 成人午夜精彩视频在线观看| 国产三级在线视频| 欧美日韩国产mv在线观看视频 | 精品亚洲乱码少妇综合久久| 1000部很黄的大片| 一夜夜www| 精品人妻一区二区三区麻豆| 日韩av在线免费看完整版不卡| 中国国产av一级| 极品教师在线视频| 欧美xxⅹ黑人| 噜噜噜噜噜久久久久久91| 欧美日韩亚洲高清精品| 色网站视频免费| 亚洲av福利一区| 97精品久久久久久久久久精品| 欧美激情国产日韩精品一区| 97超视频在线观看视频| 亚洲综合精品二区| 午夜激情欧美在线| 欧美日韩在线观看h| 精华霜和精华液先用哪个| 国产亚洲最大av| a级毛色黄片| 色5月婷婷丁香| av播播在线观看一区| 亚洲精品久久午夜乱码| 午夜激情欧美在线| 日韩欧美一区视频在线观看 | 亚洲av.av天堂| 国产成人a∨麻豆精品| 如何舔出高潮| 日韩,欧美,国产一区二区三区| 神马国产精品三级电影在线观看| 少妇的逼好多水| 插阴视频在线观看视频| 最近最新中文字幕大全电影3| 三级男女做爰猛烈吃奶摸视频| 日韩中字成人| 国产黄片视频在线免费观看| 亚洲精品中文字幕在线视频 | 纵有疾风起免费观看全集完整版 | 国产精品国产三级国产专区5o| 91精品一卡2卡3卡4卡| 人人妻人人澡欧美一区二区| 国产精品精品国产色婷婷| 最近的中文字幕免费完整| 日韩一区二区视频免费看| 国产免费一级a男人的天堂| 一级a做视频免费观看| 亚洲欧美中文字幕日韩二区| 日韩欧美一区视频在线观看 | 国产av国产精品国产| 一级av片app| 内射极品少妇av片p| 精品国产三级普通话版| 搡老妇女老女人老熟妇| 最近的中文字幕免费完整| 伦精品一区二区三区| 91av网一区二区| 91久久精品国产一区二区成人| 久久草成人影院| 亚洲无线观看免费| 欧美xxⅹ黑人| 免费电影在线观看免费观看| 六月丁香七月| 精品人妻一区二区三区麻豆| 国产一级毛片七仙女欲春2| 免费播放大片免费观看视频在线观看| 日本猛色少妇xxxxx猛交久久| 一个人观看的视频www高清免费观看| 亚洲欧美一区二区三区国产| 啦啦啦韩国在线观看视频| 亚洲欧美一区二区三区黑人 | 成人国产麻豆网| 亚洲国产精品成人综合色| 啦啦啦啦在线视频资源| 亚洲丝袜综合中文字幕| 亚洲精品日韩在线中文字幕| or卡值多少钱| 成人综合一区亚洲| 久久国产乱子免费精品| 久99久视频精品免费| 亚洲色图av天堂| 一级a做视频免费观看| 成人亚洲精品av一区二区| 国产一级毛片七仙女欲春2| 国产黄色小视频在线观看| 最近最新中文字幕大全电影3| av播播在线观看一区| 国产亚洲精品久久久com| 搞女人的毛片| 久久久久久国产a免费观看| 亚洲不卡免费看| 国产黄色免费在线视频| 久久久久网色| 黄色一级大片看看| 一级二级三级毛片免费看| 国产乱人偷精品视频| 我的老师免费观看完整版| 综合色丁香网| 少妇的逼水好多| 热99在线观看视频| 97精品久久久久久久久久精品| 成人亚洲欧美一区二区av| 欧美性猛交╳xxx乱大交人| 丝袜喷水一区| 成人国产麻豆网| 在线免费观看不下载黄p国产| 精品国产一区二区三区久久久樱花 | 日韩三级伦理在线观看| 狠狠精品人妻久久久久久综合| 国产女主播在线喷水免费视频网站 | 午夜精品一区二区三区免费看| 国产一区二区三区av在线| 毛片女人毛片| 伦理电影大哥的女人| 欧美精品国产亚洲| 天堂俺去俺来也www色官网 | 能在线免费看毛片的网站| 在线播放无遮挡| 99久久精品热视频| 秋霞在线观看毛片| ponron亚洲| 嫩草影院入口| 不卡视频在线观看欧美| 亚洲最大成人av| videos熟女内射| 街头女战士在线观看网站| 大香蕉97超碰在线| 三级男女做爰猛烈吃奶摸视频| 青青草视频在线视频观看| 午夜精品一区二区三区免费看| 国内揄拍国产精品人妻在线| 亚洲一区高清亚洲精品| 午夜日本视频在线| 久久久久精品性色| 亚洲av日韩在线播放| av卡一久久| 欧美高清成人免费视频www| 99久久中文字幕三级久久日本| 91精品国产九色| 国产免费福利视频在线观看| 一级毛片我不卡| 日韩国内少妇激情av| 2018国产大陆天天弄谢| 免费少妇av软件| 婷婷色综合大香蕉| 干丝袜人妻中文字幕| 在线观看av片永久免费下载| 99久国产av精品国产电影| 免费无遮挡裸体视频| 搡老乐熟女国产| 又黄又爽又刺激的免费视频.| 3wmmmm亚洲av在线观看| 麻豆乱淫一区二区| 久久久午夜欧美精品| 99久国产av精品国产电影| 亚洲av二区三区四区| 一个人免费在线观看电影| 亚洲人成网站在线观看播放| 国国产精品蜜臀av免费| 久久这里有精品视频免费| 丰满人妻一区二区三区视频av| 特大巨黑吊av在线直播| 亚洲欧美精品专区久久| 97精品久久久久久久久久精品| 日本-黄色视频高清免费观看| 女人十人毛片免费观看3o分钟| 日韩成人伦理影院| 综合色av麻豆| 赤兔流量卡办理| 久久久久久久久久黄片| 国产亚洲av片在线观看秒播厂 | 欧美丝袜亚洲另类| 日韩一本色道免费dvd| 一本久久精品| 美女脱内裤让男人舔精品视频| 国产黄片视频在线免费观看| 日本熟妇午夜| 国产高清有码在线观看视频| 伊人久久精品亚洲午夜| 在线观看美女被高潮喷水网站| 国产在线男女| 91久久精品国产一区二区三区| 免费观看精品视频网站| 久久久国产一区二区| 极品少妇高潮喷水抽搐| 精品久久久久久电影网| 国产久久久一区二区三区| 精品久久久久久久久亚洲| 在线免费观看不下载黄p国产| 亚洲精品aⅴ在线观看| 久久国内精品自在自线图片| 一级毛片黄色毛片免费观看视频| 亚洲精品国产av成人精品| 国产精品.久久久| 深爱激情五月婷婷| 特级一级黄色大片| 综合色丁香网| 看免费成人av毛片| 亚洲国产精品成人综合色| 免费看光身美女| 超碰av人人做人人爽久久| 18+在线观看网站| 久久久久久久午夜电影| 国产成人午夜福利电影在线观看| 我要看日韩黄色一级片| 91精品一卡2卡3卡4卡| 久久精品综合一区二区三区| 成年女人在线观看亚洲视频 | 国产人妻一区二区三区在| 日本黄大片高清| 亚洲四区av| 精品不卡国产一区二区三区| 男插女下体视频免费在线播放| 大陆偷拍与自拍| 在线观看免费高清a一片| 日本熟妇午夜| 一本久久精品| 一个人看视频在线观看www免费| 成人漫画全彩无遮挡| 日韩在线高清观看一区二区三区| 我要看日韩黄色一级片| 伦精品一区二区三区| 偷拍熟女少妇极品色| 中国美白少妇内射xxxbb| 男女国产视频网站| 亚洲无线观看免费| 视频中文字幕在线观看| 在线播放无遮挡| 听说在线观看完整版免费高清| 免费av观看视频| 嫩草影院精品99| 91精品一卡2卡3卡4卡| 最近视频中文字幕2019在线8| 午夜视频国产福利| 18禁在线播放成人免费| 精品久久久久久久久亚洲| 欧美区成人在线视频| 亚洲av男天堂| 久久精品夜色国产| 少妇高潮的动态图| 久久久久久伊人网av| 少妇人妻精品综合一区二区| 免费av不卡在线播放| 舔av片在线| av在线老鸭窝| 亚洲欧美日韩无卡精品| 日本一二三区视频观看| 搞女人的毛片| 2018国产大陆天天弄谢| 免费黄网站久久成人精品| freevideosex欧美| 亚洲综合精品二区| 成人高潮视频无遮挡免费网站| 2018国产大陆天天弄谢| 80岁老熟妇乱子伦牲交| 久久综合国产亚洲精品| 国产成人freesex在线| 校园人妻丝袜中文字幕| 三级经典国产精品| 亚洲婷婷狠狠爱综合网| 欧美xxⅹ黑人| 国产黄色视频一区二区在线观看| 亚洲精品日韩在线中文字幕| 国产精品伦人一区二区| 婷婷六月久久综合丁香| 午夜久久久久精精品| 美女国产视频在线观看| 中文字幕久久专区| 嫩草影院精品99| 亚洲,欧美,日韩| 午夜亚洲福利在线播放| 伦理电影大哥的女人| 大片免费播放器 马上看| 国产老妇女一区| 一区二区三区乱码不卡18| av.在线天堂| 日韩亚洲欧美综合| 国产乱人视频| 久久久国产一区二区| 精品久久久噜噜| 亚洲内射少妇av| 欧美变态另类bdsm刘玥| 日本av手机在线免费观看| 国产精品一区二区三区四区免费观看| 久久午夜福利片| 亚洲电影在线观看av| 成年人午夜在线观看视频 | 高清av免费在线| a级一级毛片免费在线观看| 中国国产av一级| 不卡视频在线观看欧美| 国模一区二区三区四区视频| 午夜福利网站1000一区二区三区| a级毛色黄片| 精华霜和精华液先用哪个| 亚洲不卡免费看| 丰满人妻一区二区三区视频av| 国产探花在线观看一区二区| 国国产精品蜜臀av免费| 中文资源天堂在线| 国产成人a∨麻豆精品| 在线天堂最新版资源| 午夜精品在线福利| 国产极品天堂在线| 熟妇人妻不卡中文字幕| av又黄又爽大尺度在线免费看| a级一级毛片免费在线观看| 美女xxoo啪啪120秒动态图| 黄色配什么色好看| 美女cb高潮喷水在线观看| av在线蜜桃| 韩国av在线不卡| 五月伊人婷婷丁香| 男女那种视频在线观看| 国产精品爽爽va在线观看网站| 一个人看视频在线观看www免费| 六月丁香七月| 中文天堂在线官网| 亚洲精品456在线播放app| 国产伦精品一区二区三区视频9| 中文在线观看免费www的网站| 亚洲国产欧美在线一区| 国产伦理片在线播放av一区| 嫩草影院入口| 日韩欧美 国产精品| 久久99热6这里只有精品| 只有这里有精品99| 国产人妻一区二区三区在| 国产成人精品一,二区| 精品不卡国产一区二区三区| av在线天堂中文字幕| 免费观看精品视频网站| 亚洲精品乱久久久久久| 国产激情偷乱视频一区二区| 在线观看一区二区三区| 亚洲一区高清亚洲精品| 精品人妻偷拍中文字幕| 国语对白做爰xxxⅹ性视频网站| 国产成人精品福利久久| 午夜亚洲福利在线播放| 国产精品不卡视频一区二区| 国产一区二区亚洲精品在线观看| 中文字幕久久专区| 日韩三级伦理在线观看| 老女人水多毛片| 亚洲av成人精品一二三区| 亚洲av不卡在线观看| 亚洲自拍偷在线| 韩国高清视频一区二区三区| 亚洲av国产av综合av卡| 欧美xxxx性猛交bbbb| 国产精品综合久久久久久久免费| 久久国内精品自在自线图片| 欧美三级亚洲精品| 美女cb高潮喷水在线观看| 在线天堂最新版资源| 亚洲欧美清纯卡通| 国产老妇女一区| 老司机影院成人| 国产精品福利在线免费观看| av黄色大香蕉| 一级毛片电影观看| 成年版毛片免费区| 国产人妻一区二区三区在| 少妇人妻一区二区三区视频| 丝袜喷水一区| 欧美一区二区亚洲| 夜夜看夜夜爽夜夜摸| 免费在线观看成人毛片| www.色视频.com| 一级毛片aaaaaa免费看小| 亚洲av一区综合| av天堂中文字幕网| 秋霞在线观看毛片| 免费av毛片视频| 精品久久久久久久人妻蜜臀av| 亚洲欧美日韩卡通动漫| 边亲边吃奶的免费视频| 成人亚洲精品av一区二区| 亚洲熟妇中文字幕五十中出| 日本熟妇午夜| 国产片特级美女逼逼视频| 哪个播放器可以免费观看大片| 国产 一区 欧美 日韩| 成人特级av手机在线观看| 欧美不卡视频在线免费观看| 午夜爱爱视频在线播放| 最新中文字幕久久久久| 欧美潮喷喷水| 国产av国产精品国产| 亚洲av日韩在线播放| 亚洲成人一二三区av| 亚州av有码| 熟妇人妻久久中文字幕3abv| 日本欧美国产在线视频| 91av网一区二区| 欧美一级a爱片免费观看看| 校园人妻丝袜中文字幕| 人妻夜夜爽99麻豆av| 特大巨黑吊av在线直播| 2018国产大陆天天弄谢| 色综合色国产| 狂野欧美白嫩少妇大欣赏| 婷婷六月久久综合丁香| 18+在线观看网站| 亚洲国产最新在线播放| 自拍偷自拍亚洲精品老妇| 国产亚洲av片在线观看秒播厂 | 啦啦啦啦在线视频资源| 亚洲av免费在线观看| 内射极品少妇av片p| 男人和女人高潮做爰伦理| 97人妻精品一区二区三区麻豆| 日韩欧美国产在线观看| 99久久中文字幕三级久久日本| 真实男女啪啪啪动态图| 日韩欧美三级三区| 黄色欧美视频在线观看| 国产精品一区二区三区四区久久| 国产亚洲av片在线观看秒播厂 | 18禁在线无遮挡免费观看视频| 国产老妇女一区| 能在线免费看毛片的网站| .国产精品久久| 亚洲婷婷狠狠爱综合网| 亚洲经典国产精华液单| 91精品伊人久久大香线蕉| 色综合色国产| 日本免费a在线| 久久久久免费精品人妻一区二区| 日本猛色少妇xxxxx猛交久久| 夜夜爽夜夜爽视频| 免费av毛片视频| av线在线观看网站| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 搡老乐熟女国产| 中国美白少妇内射xxxbb| 欧美日韩视频高清一区二区三区二| 熟妇人妻久久中文字幕3abv| 在线观看免费高清a一片| 国产精品久久久久久久电影| 简卡轻食公司| 日产精品乱码卡一卡2卡三| 免费看日本二区| 久久99热这里只有精品18| 最近最新中文字幕大全电影3| 国产成人福利小说| 国产精品人妻久久久久久| 一区二区三区四区激情视频| 精品国产一区二区三区久久久樱花 | 免费黄网站久久成人精品| 日韩大片免费观看网站| a级一级毛片免费在线观看| 欧美性感艳星| 国产精品一区二区三区四区免费观看| 国产黄色视频一区二区在线观看| 久久久久久伊人网av| 久久精品国产亚洲av涩爱| 国产精品一区www在线观看| 免费av毛片视频| 日韩国内少妇激情av| 亚洲人与动物交配视频| 亚洲一级一片aⅴ在线观看| 成人高潮视频无遮挡免费网站| 欧美xxxx性猛交bbbb| 七月丁香在线播放| 国产成人freesex在线| 国产精品美女特级片免费视频播放器| 日韩制服骚丝袜av| 国产伦在线观看视频一区| 男人爽女人下面视频在线观看| 久久精品久久久久久噜噜老黄| kizo精华| 中文乱码字字幕精品一区二区三区 | 人妻系列 视频| 亚洲熟妇中文字幕五十中出| 人人妻人人澡人人爽人人夜夜 | 久久久亚洲精品成人影院| 国产 一区 欧美 日韩| 欧美zozozo另类| 亚洲精品,欧美精品| 亚洲丝袜综合中文字幕| 久久久久九九精品影院| 精品久久久久久久久亚洲|